Five Scientific Posters Supporting the Efficacy and Tolerability of Once-Daily Lurasidone - A New Atypical Antipsychotic Treatment for Adults with Schizophrenia

Five Scientific Posters Supporting theFive Scientific Posters Supporting the Efficacy and Tolerability of Once-Daily Lurasidone - A New Atypical Antipsychotic Treatment for Adults with Schizophrenia PR Newswire BARCELONA, Spain, October 14, 2013 thOn the occasion of the 26 European College of Neuropsychopharmacology Congress (ECNP), with educational financial support provided by Takeda and Sunovion Pharmaceuticals Europe, new data was presented showing both short and long-term efficacy for lurasidone, an atypical antipsychotic treatment for schizophrenia. These data also showed lurasidone to have early separation from placebo, a rapid [1] [1],[2],[3],[4]onset of action , a favourable side effect profile and to be a well-tolerated, efficacious option for patients with schizophrenia switching [4]medication. Lurasidone has been approved in US, Canada and Switzerland and is currently under regulatory review in Europe. The data included a post-hoc analysis of double-blind controlled studies showing how insight (awareness of illness), when measured by PANSS score, was significantly improved for clinically unstable patients given once- daily lurasidone 80 mg, lurasidone 160 mg and active control quetiapine XR [5]600 mg, compared to placebo, after 6 weeks . At week 32, insight was significantly greater for those treated with lurasidone compared with quetiapine XR. Increased insight was shown to predict improvements in specific cognitive measures.